Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774604 · ClinicalTrials.gov registry record · Phase 3
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
A Phase 3 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
NCT01774604 is a Phase 3 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 449 participants.
The verdict
NCT01774604, a Phase 3 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
Interventions
- DRUG Placebo
- DRUG Indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774604
The ClinicalTrials.gov registry entry for NCT01774604 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01774604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774604 about?
NCT01774604 is a clinical study titled "Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis". The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
What is the current status of trial NCT01774604?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2013-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01774604?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG).
Who is sponsoring clinical trial NCT01774604?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.